Department of Immunoendocrinology, Chair of Endocrinology, Medical University of Lodz, Pomorska 251, 92-213, Lodz, Poland.
Clinic of Endocrinological and General Surgery, Chair of Endocrinology, Medical University of Lodz, Pabianicka 62, 93-513 Lodz, Poland.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Mar;164(1):77-83. doi: 10.5507/bp.2019.018. Epub 2019 May 23.
The rising incidence of thyroid cancer observed in the last few decades requires an improvement in diagnostic tools and management techniques for patients with thyroid nodules.
The aim of this study was to assess serum concentrations of IGF-1 and IGF-1R in patients diagnosed with thyroid cancers.
36 patients diagnosed with papillary thyroid cancer (PTC), 11 subjects with follicular thyroid cancer (FTC), 9 patients with anaplastic thyroid cancer (ATC) and 19 subjects with multinodular nontoxic goiter (MNG) were enrolled to the study. The control group (CG) consisted of 20 healthy volunteers. Blood samples were collected one day before surgery. Serum IGF-1 and IGF-1R concentrations were measured using specific ELISA methods.
Significantly higher concentrations of IGF-1 were found in patients with PTC as compared with controls but not that obtained from subjects diagnosed with MNG. The concentration of IGF-1R was significantly elevated in subjects with PTC and ATC as compared with healthy volunteers. Similarly, patients diagnosed with PTC or ATC presented significantly higher serum concentration of IGF-1R in comparison to the MNG group.
Our results show that the IGF-1 - IGF-1R axis plays a significant role in the development of PTC and ATC and imply that serum concentrations of both cytokines may be considered as additional markers for the differentiation of malignancies during the preoperative diagnosis of patients with thyroid gland tumors. These results indicate that IGF-1R serum concentrations allow us to differentiate between MNG and PTC or ATC. Moreover IGF-1R serum values appear to be better predictor of PTC and ATC than IGF-1 concentrations.
在过去几十年中，观察到甲状腺癌的发病率上升，这就需要改进甲状腺结节患者的诊断工具和管理技术。
本研究旨在评估诊断为甲状腺癌的患者的血清 IGF-1 和 IGF-1R 浓度。
将 36 例诊断为甲状腺乳头状癌（PTC）的患者、11 例滤泡状甲状腺癌（FTC）患者、9 例间变性甲状腺癌（ATC）患者和 19 例多结节性非毒性甲状腺肿（MNG）患者纳入研究。对照组（CG）由 20 名健康志愿者组成。采集手术前一天的血样。使用特定的 ELISA 方法测量血清 IGF-1 和 IGF-1R 浓度。
与对照组相比，PTC 患者的 IGF-1 浓度明显升高，但与 MNG 患者相比则不然。与健康志愿者相比，PTC 和 ATC 患者的 IGF-1R 浓度明显升高。同样，与 MNG 组相比，诊断为 PTC 或 ATC 的患者的血清 IGF-1R 浓度也明显升高。
我们的结果表明，IGF-1-IGF-1R 轴在 PTC 和 ATC 的发展中起重要作用，并暗示这两种细胞因子的血清浓度可作为甲状腺肿瘤患者术前诊断中恶性肿瘤分化的附加标志物。这些结果表明，IGF-1R 血清浓度可区分 MNG 和 PTC 或 ATC。此外，与 IGF-1 浓度相比，IGF-1R 血清值似乎是 PTC 和 ATC 的更好预测指标。
